Report: Alzheimer's biomarker market to reach $9B in decade

Protein biomarkers for Alzheimer's disease will represent a $9 billion market over the next decade, according to ProteoMonitor, reporting on a study commissioned by proteomics firm Proteome Sciences. That's why biomarker firms such as Quanterix, Rules-Based Medicine and NextGen Sciences have focused so much on Alzheimer's lately.

"I think it's becoming a much higher-profile disease area," Proteome Sciences CEO Christopher Pearce told ProteoMonitor. "[It's] looking to be one of the hotter areas simply because of the size and economic costs it's delivering."

It's unclear, however, who came up with the $9 billion figure. Pearce would only say that the report was prepared by "a former senior industry figure with considerable expertise in field," according to ProteoMonitor. The U.K.-based company reported that its revenues for the year jumped more than seven-fold to $16.3 million, largely due to a payment to the company by Sanofi-Aventis to settle a dispute over a sales and transfer agreement.

- read the story in ProteoMonitor

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.